Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | ATM |
| Variant | E2039K |
| Impact List | missense |
| Protein Effect | loss of function - predicted |
| Gene Variant Descriptions | ATM E2039K lies within the FAT domain of the Atm protein (UniProt.org). E2039K retains protein stability but results in decreased phosphorylation of Atm downstream targets in response to irradiation in culture (PMID: 19431188), and therefore, is predicted to lead to a loss of Atm protein function. |
| Associated Drug Resistance | |
| Category Variants Paths |
ATM mutant ATM inact mut ATM E2039K |
| Transcript | NM_000051.4 |
| gDNA | chr11:g.108316030G>A |
| cDNA | c.6115G>A |
| Protein | p.E2039K |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| XM_017017790.2 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_047426976.1 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_005271562.6 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_011542840.3 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| NM_000051.3 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_047426978.1 | chr11:g.108317454G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_006718843 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_047426975.1 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_047426977.1 | chr11:g.108317454G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_011542842.3 | chr11:g.108317454G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| NM_000051.4 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_017017791 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_005271561 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_011542843 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_011542842 | chr11:g.108317454G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_047426979.1 | chr11:g.108317454G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_006718843.5 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_017017791.1 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_017017790 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_006718843.4 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_011542840 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_011542840.4 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_005271562 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_005271562.5 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_011542843.2 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_011542843.3 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_017017789 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| NM_001351834.1 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_017017790.3 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_017017789.2 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| NM_000051 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_011542842.4 | chr11:g.108317454G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| NM_001351834.2 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|